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Abstract
Summary The variability of serum osteoprotegerin (OPG)
and soluble RANKL (sRANKL) along the 24-h cycle was
assessed in 20 healthy women. No rhythmic variations of
serum OPG, sRANKL or sRANKL/OPG ratio were detected
as a group phenomenon. Timing of sampling is unlikely to
influence the results of measurements of circulating OPG
and sRANKL.
Introduction Physiological bone turnover shows diurnal
variations. The aim of the study was to assess variability of
OPG and sRANKL serum levels along the 24-h cycle.
Methods Blood was collected from 20 healthy women
(median age 31 years, range 25–65 years) at 4-h intervals
between 08:00 and 24:00 and at 2-h intervals between 24:00
and 08:00. Serum albumin, cortisol, osteocalcin (OC), C-
terminal telopeptide of type I collagen (CTX), OPG and total
sRANKL were measured. Temporal variations were
assessed by the COSINOR model.
Results Circadian rhythms of cortisol and albumin docu-
mented a normal synchronization within the circadian
structure. Serum OC and CTX showed rhythmic variations,
peaking at night-time. Rhythmic variations of serum OPG,
sRANKL and sRANKL/OPG ratio were not detected as a
group phenomenon. On an individual basis, rhythmic changes
were detected in ten patients for OPG and eight patients for
sRANKL, with very small amplitudes and heterogeneous
acrophases.
Conclusions The absence of consistent rhythmic variations
of circulating OPG and sRANKL levels may reflect the
absence of rhythmic variations of their expression in the
bone microenvironment. Were this the case, the nocturnal
rise of bone resorption should be accounted for by different,
not RANKL/OPG-mediated factors. Since circulating OPG
and sRANKL may derive from sources other than bone,
rhythmicity could be masked by non-rhythmic or non-
synchronized rhythmic expression in these sources. Timing
of sampling is unlikely to influence the results of measure-
ments of circulating OPG and sRANKL.
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Introduction
The signaling system consisting of RANK ligand (RANKL),
its receptor RANK and its decoy receptor osteoprotegerin
(OPG) has a key role in the pathophysiology of the bone
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microenvironment [1, 2]. Given the availability of specific
antibodies, interest has grown in the measurement of circu-
lating OPG and soluble RANKL (sRANKL), which could give
insight into the regulatory mechanisms of the system and
provide novel markers in a number of diseases [3, 4].
Physiological bone turnover increases at night-time.
Putative synchronizing hormones include parathyroid hor-
mone, melatonin, glucocorticoids and food-dependent
peptides, such as glucagon-like peptide 2 [5–12]. Expres-
sion of clock genes in osteoblasts has recently been
demonstrated, and is consistent with the concept of a bone
peripheral clock [13, 14].
Rhythmic changes of RANKL and/or OPG expression in
the bone microenvironment could contribute to variation of
bone resorption and be of relevance for timing of
administration of new anti-RANKL agents. With regard to
serum levels of sRANKL and OPG, variability along the
24-h cycle should be taken into account when they are
investigated as markers of skeletal or vascular diseases.
Only a few studies have addressed the issue of possible
rhythmicity of circulating OPG [15–17], whereas there are
no data on serum sRANKL. The aim of the study was to
assess the variability of OPG and sRANKL serum levels
along the 24-h cycle in healthy women.
Subjects, materials and methods
Twenty healthy women volunteered to participate in this study
(median age 31 years, range 25–65 years); 17 women were
pre-menopausal. The subjects studied were members of the
medical staff or their relatives, were non-smokers and were
not under the influence of bone-active medications. Pre-
menopausal women were eumenorrhoic. General laboratory
screening gave no indication of specific organ dysfunction.
Bone mineral density was not assessed, since subjects had no
specific risk factors for osteoporosis. The study was
performed in accordance with guidelines on good clinical
practice and the Declaration of Helsinki, and subsequent
relevant amendments, and was approved by the local ethics
committee. All subjects gave written informed consent.
Blood samples were collected at 4-h intervals between
08:00 and 24:00, and at 2-h intervals between 24:00 and
08:00. All subjects were given a standard hospital diet
with three equicaloric meals at approximately 07:00,
13:00 and 19:00. They were freely ambulant but avoided
moderate to heavy exercise throughout the 24-h sampling
period; they were not hospitalized during the day and
usually returned home between one urine and blood
collection and the next one. They were hospitalized at
night. They laid down to sleep at 23:00 and awoke at
07:00. Routine biochemical analysis was performed on
fresh samples; aliquots were stored at −20°C for up to
6 months before being assayed. Serum osteocalcin (OC)
was measured by radioimmunoassay using a monoclonal
antibody that binds intact OC and fragments 1–43, 20–49
and 20–44 (Osteocalcina Myria, Technogenetics, Milan,
Italy). Serum C-terminal telopeptide of type I collagen
(CTX) was measured by enzyme-linked immunosorbent
assay (ELISA) (Nordic Bioscience Diagnostic, Herlev,
Denmark). ELISAs for both OPG and sRANKL were
performed directly by Immundiagnostik AG (Bensheim,
Germany). OPG was measured by a pair of specific anti-
human OPG antibodies (capture monoclonal antibody and
detection biotinylated goat polyclonal antibody). For
sRANKL, samples were first added an OPG solution and
then put into microplate wells coated with a goat
polyclonal anti-human OPG antibody. Subsequently, a
biotinylated monoclonal anti-human sRANKL antibody
was added. All the samples were shipped at the same time
and were assayed in duplicate with reagents from the same
lot. Measurement was repeated for duplicate coefficients of
variation (CVs) >20% and values out of the calibration
curve. Measuring ranges, minimum detectable concentra-
tions and intra- and inter-assay coefficients of variation
were as follows: OC 2.2–64.3 ng/ml, 0.3 ng/ml, 3.5% and
5.6%; CTX 0.156–2.562 ng/ml, 0.01 ng/ml, 2.5% and 9%;
OPG 3.13–25 pmol/l, 0.14 pmol/l, <10% and <10%;
sRANKL 2.2–60 pmol/l, <0.5 pmol/l, <5% and <10%.
For each individual data series, the coefficient of
variation was calculated and the single COSINOR analysis
was performed. A predetermined period (τ=24 h for
circadian, 12 h for circasemidian) was chosen to fit a
cosine curve to the data series. Correlation coefficient
constant and mean square error determine the goodness-
of-fit of the cosine curve [18]. The analysis yields three
main parameters: midline estimating statistics of the
rhythm (MESOR) of the fitted cosine curve, acrophase
(occurrence of the estimated peak time, which may not be
coincident with the time at which maximum concentration
was observed), and amplitude (half the difference between
the highest and the lowest points of the fitted cosine
curve). Data obtained from single COSINOR analysis
were further analyzed by the population-mean COSINOR
procedure so that statistically validated parameters for the
group could be obtained. Significance was determined by
the zero-amplitude (no rhythm) test. Data were analyzed
as absolute values for the considered analyte and then as a
percent value of each relevant MESOR, so that inter-
individual variability was minimized.
Correlations among variables were assessed by Spear-
man R analysis. P<0.05 was considered as significant.
All statistics tests were performed with SPSS for Windows
software, version 12.0.2, and STATISTICA for Windows,
version 6.1.
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Circadian rhythms of serum cortisol (MESOR 116.2 nmol/l,
amplitude 60.9 nmol/l, acrophase 09:30, P<0.0001) and
albumin (MESOR 4,103 mg/dl, amplitude 214 mg/dl,
acrophase 15:30, P=0.04) were well apparent. Serum OC
and CTX showed significant rhythmic variations, with
acrophases at night-time (Fig. 1).
Serum OPG and sRANKL showed wide inter-individual
variability (serum concentrations at 08:00, for OPG median
3.3 pmol/l, range 1.2–7.9 pmol/l; for sRANKL 478 pmol/l,
95–5,444 pmol/l) and intra-individual variations (individual
coefficient of variations, for OPG 14%, 6–30%; for
sRANKL 16%, 5–51%). No correlation between serum
OPG and sRANKL was found with age. Rhythmic
variations of serum OPG, sRANKL and sRANKL/OPG
ratio could not be detected with statistical significance as a
group phenomenon (Fig. 2). On an individual basis,
rhythmic changes, with very small amplitudes (OPG
10.8%, 5.5–22.2%; sRANKL 11.8%, 5.6–22.2%) and
heterogeneous acrophases, were detected in ten patients
for OPG and in eight patients for sRANKL. No difference
in age or menopausal status was found between subjects
with and those without rhythmic changes. Similar results
were obtained when data were adjusted for inter-individual
variability and computed as percent changes from MESOR,
and when the three post-menopausal women were excluded
from analysis. No correlation was found between serum
OPG, sRANKL levels and sRANKL/OPG ratio, on the one
hand, and serum CTX or OC, on the other.
Fig. 2 Variations of serum OPG (a) and total sRANKL (b) along a
24-h period. Circles represent individual values at specific time points;
curves are cosine curves extrapolated by a population-mean
COSINOR procedure. The highest values of serum OPG and
sRANKL, respectively, belonged to three different subjects (labeled
2, 3 and 4)
Fig. 1 Variations in serum OC (a) and CTX (b) along a 24-h period.
Circles represent individual values at specific time points; curves are
cosine curves extrapolated by a population-mean COSINOR proce-
dure. The highest values of serum OC all belonged to the same subject
(labeled 1)
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Discussion
Pre-analytical and analytical factors may contribute to the
striking differences of OPG values reported in different
studies [4, 19–21]. Possible variations of circulating OPG
and sRANKL along the 24-h cycle have not been
adequately investigated. In this work, rhythmometric data
of serum cortisol and albumin served to assess synchroni-
zation within the circadian structure as it is held in
chronobiological studies. Serum OC and CTX peaked at
night, as previously reported [5–9]. Notably, OC circulates
as both the intact molecule and a number of fragments,
generated both by serum proteases in blood circulation and,
to a lesser extent, by osteoclastic cysteine proteases during
bone resorption [22]. Since different assays show different
specificities for the various fragments [23], and our assay
detects different fragments besides the intact molecule, we
cannot exclude the fact that measured OC might somehow
reflect bone resorption in addition to formation. While
rhythmicity of serum OC has been linked to cortisol
secretion [6], diurnal variation in bone resorption is mainly
due to food intake through the release of food-dependent
peptides, such as glucagon-like peptide 2, and is diminished
during fasting [10–12].
As far as serum OPG and sRANKL are concerned, we
did not find a significant rhythm, as a group phenomenon,
for these two analytes. On an individual basis, rhythmic
changes were detected in a subgroup of subjects, with small
amplitudes and heterogeneous acrophases; such inconsis-
tent changes are unlikely to be relevant physiologically or
as a source of significant pre-analytical variability. Notably,
both OPG and sRANKL showed wide inter-individual
variability, and substantial intra-individual variations were
observed in a small proportion of subjects. Available
information on variation of circulating OPG along the
24-h cycle is scanty and contradictory. Joseph et al. [15] did
find a significant rhythmicity for OPG in a group of four
men and four women. In a group of six women and three
men, Tarquini et al. [16] found a circasemidian, rather than
circadian, variation in circulating OPG, with a quite small
amplitude (<5%); we failed to confirm such a circasemidian
rhythm in our population. Most recently, Ohta et al. [17]
have studied 15 young female volunteers from whom blood
was collected three times, at 6 h intervals. The authors did
not find an appreciable diurnal variation. Differences in
study design (gender, age, sampling sequence, assays and
data processing) could explain discrepancies.
Our study is limited to a group of mainly pre-menopausal
women, in different phases of the ovarian cycle; rhythmic
changes may still occur in luteal vs follicular phase, in elderly
women, or in men. Moreover, we did not specifically address
the effects of food intake (the main determinant of diurnal
variation of bone resorption) on the analytes measured.
Finally, we assessed total sRANKL, and we have no data on
the free form of the molecule. RANKL is produced as a
45 kDa membrane-associated protein, as a 31 kDa soluble
protein by proteolytic cleavage, or as a 39.5 kDa soluble
protein following expression of the hRANKL3 isoform [24].
In murine models, the membrane form is more active than
the soluble ones [24–26]. sRANKL is present in blood
circulation both in the free form and as a complex with OPG,
but the sensitivity of available assays is still insufficient to
detect the free form of sRANKL in a significant proportion
of healthy individuals [3, 4]. However, we cannot exclude
rhythmic changes of free sRANKL levels, as a result of
rhythmic variations of potential (presently unknown)
sRANKL-binding molecules other than OPG.
A possible explanation for our results could be viewed in
long plasma half-lives of the molecules. No data are
available on sRANKL, and the only data on OPG plasma
half-life come from a single animal study. In rats intrave-
nously injected with human monomeric or homodimeric
OPG, the elimination curves of the two forms in serum were
well fitted to the two-compartment model, with β1/2 values
of less than 30 min for both forms [27]. If these values
roughly apply to humans, the absence of variation in OPG
along the 24-h cycle is not accounted for by its half-life.
The absence of rhythmic variations could be due to
substantially stable release of these molecules from the
bone microenvironment into the bloodstream. Were this the
case, one could suggest that the nocturnal rise in osteoclast
activity is mediated by pathways independent of RANKL/
OPG balance. Alternatively, since circulating OPG and
sRANKL derive from several sources [1–4], rhythmic
changes of gene expression and release of these products
in the extracellular space could, indeed, occur in specialized
cells such as those resident in bone. The circulating pool,
however, could mask variations of tissue-specific isoforms,
with either non-rhythmic or non-synchronized isoforms
coming from other tissues. Indeed, OPG is expressed in
both endothelial and vascular smooth muscle cells, and a
number of Authors have recently suggested that serum
OPG might be a marker of atherosclerotic disease, rather
than bone metabolism [3, 4, 28].
Whatever be the explanation for our results, they are of
relevance for studies dealing with circulating OPG and
sRANKL, as timing of sampling is unlikely to influence the
results of measurements.
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